The Bevacizumab Biosimilar Market is experiencing substantial growth as healthcare systems worldwide seek cost-effective alternatives to expensive biologic cancer therapies. Bevacizumab, a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), has been a cornerstone treatment for multiple cancer types including colorectal, lung, breast, ovarian, and glioblastoma. However,...